PTCH1 and neoplasm: Secondary endpoints in this study include evidence of clinical activity (progression-free survival, PSA response, overall survival) as well as correlative markers, including change in expression of other components of the Hh pathway (PTCH1, GLI2), and correlation of change in GLI1 mRNA expression between skin and tumor biopsies.